AR026267A1 - CYTOTOXIC HETEROCICLIC AGENTS. - Google Patents

CYTOTOXIC HETEROCICLIC AGENTS.

Info

Publication number
AR026267A1
AR026267A1 ARP000105664A ARP000105664A AR026267A1 AR 026267 A1 AR026267 A1 AR 026267A1 AR P000105664 A ARP000105664 A AR P000105664A AR P000105664 A ARP000105664 A AR P000105664A AR 026267 A1 AR026267 A1 AR 026267A1
Authority
AR
Argentina
Prior art keywords
formula
heterociclic
cytotoxic
agents
compounds
Prior art date
Application number
ARP000105664A
Other languages
Spanish (es)
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers filed Critical Univ Rutgers
Publication of AR026267A1 publication Critical patent/AR026267A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

Proporciona compuestos de formula 1 donde R1-R8 A-G tiene cualquier de los significados significados definidos en la especificacion, y sus salesfarmacéuticamente aceptables. También proporciona composiciones farmacéuticas que incluyen un compuesto de formula 1, procesos para preparar compuestos deformula 1, intermediarios utiles para preparar compuestos de formula a y métodos terapéuticos para tratar cáncer usando compuestos de formula 1.It provides compounds of formula 1 where R1-R8 A-G has any of the meanings defined in the specification, and their pharmaceutically acceptable salts. It also provides pharmaceutical compositions that include a compound of formula 1, processes for preparing compounds of formula 1, intermediates useful for preparing compounds of formula a and therapeutic methods for treating cancer using compounds of formula 1.

ARP000105664A 1999-10-29 2000-10-27 CYTOTOXIC HETEROCICLIC AGENTS. AR026267A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16254099P 1999-10-29 1999-10-29

Publications (1)

Publication Number Publication Date
AR026267A1 true AR026267A1 (en) 2003-02-05

Family

ID=22586069

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105664A AR026267A1 (en) 1999-10-29 2000-10-27 CYTOTOXIC HETEROCICLIC AGENTS.

Country Status (6)

Country Link
EP (1) EP1228045A2 (en)
JP (1) JP2003513079A (en)
AR (1) AR026267A1 (en)
AU (1) AU1236401A (en)
CA (1) CA2389312A1 (en)
WO (1) WO2001032631A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60228484D1 (en) 2001-11-14 2008-10-02 Univ Rutgers CYTOTOXIC AGENTS
EP1465625B1 (en) 2001-11-14 2010-02-03 Rutgers, The State University Solubilized topoisomerase poisons
AU2002365161B2 (en) * 2001-11-14 2008-07-03 Rutgers, The State University Solubilized topoisomerase poison agents
DE60225943T2 (en) 2001-11-14 2009-01-29 Rutgers, The State University Topoisomerase GIFT FUNDS
US6989387B2 (en) 2002-08-09 2006-01-24 Rutgers, The State University Of New Jersey Nitro and amino substituted topoisomerase agents
US6992089B2 (en) 2002-08-09 2006-01-31 Rutgers, The University Of New Jersey Nitro and amino substituted topoisomerase agents
WO2004014862A1 (en) 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted heterocycles as topoisomerase i targeting agents
JP4774212B2 (en) * 2002-11-12 2011-09-14 ラトガーズ、ザ・ステイト・ユニバーシテイ・オブ・ニユー・ジヤージー Topoisomerase-targeting agent
JP4500689B2 (en) 2002-12-26 2010-07-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 Selective estrogen receptor modulator
DE102008022221A1 (en) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitors of human aldosterone synthase CYP11B2
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
WO2010102219A1 (en) 2009-03-06 2010-09-10 Rutgers, The State University Of New Jersey Methylenedioxybenzo [i] phenanthridine derivatives used to treat cancer
WO2010127363A1 (en) 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
SI3122426T1 (en) 2014-03-28 2023-04-28 Duke University Treating breast cancer using selective estrogen receptor modulators
US11091498B2 (en) 2016-04-04 2021-08-17 Rutgers, The State University Of New Jersey Topoisomerase poisons

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045272A1 (en) * 1997-04-07 1998-10-15 Latrobe University Topoisomerase inhibitors

Also Published As

Publication number Publication date
WO2001032631A3 (en) 2002-02-21
CA2389312A1 (en) 2001-05-10
JP2003513079A (en) 2003-04-08
AU1236401A (en) 2001-05-14
WO2001032631A2 (en) 2001-05-10
EP1228045A2 (en) 2002-08-07

Similar Documents

Publication Publication Date Title
AR026267A1 (en) CYTOTOXIC HETEROCICLIC AGENTS.
BG106586A (en) Pyrazolopyramidines as therapeutic agents
CY1110631T1 (en) SOLVED POETRY POINTS
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
AR007828A1 (en) COMPOUNDS DERIVED FROM PIRIDILPIRROL, PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
CR20140368A (en) DERIVATIVES AND COMPOSITIONS OF ISOINDOL 4´-0-SUBSTITUTES, COMPOSITIONS THAT INCLUDE THEM AND METHODS OF USE OF THE SAME (DIVISIONAL 11036)
MY128765A (en) Novel benzoimidazole derivatives useful as antiproliferative agents.
SV2003000633A (en) NEW TIADIAZOLS AND OXADIAZOLS AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASA-7
DE60112974D1 (en) Carbolinderivate
DE60216233D1 (en) Carbolinderivate
SE9903997D0 (en) New compounds
EE200000472A (en) Antineoplastic agents
UY27685A1 (en) INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS, AND PROCEDURES FOR USE
ATE297904T1 (en) HALO-ALKOXYCARBONYL COMPOUNDS
AR018162A1 (en) SUBSTITUTED PIRROLS, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION
ATE424200T1 (en) SOLUBILIZED TOPOISOMERASE POISON AGENT
AR020563A1 (en) TIA-ALQUINOIC COMPOUNDS (POLI) AND THEIR DERIVATIVES, COMPOSITIONS THAT INCLUDE THEM AND THEIR USE
EP1109560A4 (en) Compounds useful as aicarft inhibitors
AU2002364953A8 (en) Topoisomerase poison agents
ATE266029T1 (en) SUBSTITUTED PYRROLOBENZIMIDAZOLE DERIVATIVES FOR ANTI-INFLAMMATORY
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
MXPA03003971A (en) Indole derivatives as pde5-inhibitors.
PT1017681E (en) PHARMACEUTICAL AND INTERMEDIATE COMPOUNDS
UY26224A1 (en) PHARMACEUTICAL COMPLEX LAW 17164 ART. 127

Legal Events

Date Code Title Description
FB Suspension of granting procedure